BRPI1002087A2 - Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica - Google Patents

Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica Download PDF

Info

Publication number
BRPI1002087A2
BRPI1002087A2 BRPI1002087-0A BRPI1002087A BRPI1002087A2 BR PI1002087 A2 BRPI1002087 A2 BR PI1002087A2 BR PI1002087 A BRPI1002087 A BR PI1002087A BR PI1002087 A2 BRPI1002087 A2 BR PI1002087A2
Authority
BR
Brazil
Prior art keywords
alpha
treatment
chronic fatigue
fatigue syndrome
antitripsin
Prior art date
Application number
BRPI1002087-0A
Other languages
English (en)
Inventor
Garcia Quintana Ana
Alegre Martin José
Original Assignee
Grifols, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols, S.A. filed Critical Grifols, S.A.
Publication of BRPI1002087A2 publication Critical patent/BRPI1002087A2/pt
Publication of BRPI1002087B1 publication Critical patent/BRPI1002087B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE ALFA-1-ANTITRIPSINA PARA A PREPARAçãO DE MEDICAMENTOS PARA O TRATAMENTO DA SìNDROME DA FADIGA CRÈNICA. A presente invenção refere-se ao uso de aífa-1-antitripsina para a preparação de medicamentos eficazes para o tratamento da síndrome da fadiga crónica. Além disso, a presente invenção refere-se ao uso de plasma ou de outras formas terapêuticas com um teor de alfa-1-antitripsina suficiente para obter uma dose de 6 mg ou mais de alfa-1-antitripsina por kg de peso corporal em uma frequência entre 1 e 31 dias.
BRPI1002087-0A 2009-06-30 2010-06-24 Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica BRPI1002087B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (2)

Publication Number Publication Date
BRPI1002087A2 true BRPI1002087A2 (pt) 2012-03-13
BRPI1002087B1 BRPI1002087B1 (pt) 2019-07-02

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1002087-0A BRPI1002087B1 (pt) 2009-06-30 2010-06-24 Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica

Country Status (16)

Country Link
US (1) US9205134B2 (pt)
EP (1) EP2289540B1 (pt)
JP (1) JP5231490B2 (pt)
CN (1) CN101934071B (pt)
AR (1) AR077123A1 (pt)
AU (1) AU2010202203B2 (pt)
BR (1) BRPI1002087B1 (pt)
CA (1) CA2706212C (pt)
CL (1) CL2010000575A1 (pt)
ES (2) ES2332645B1 (pt)
MX (1) MX2010006125A (pt)
NZ (1) NZ585890A (pt)
PL (1) PL2289540T3 (pt)
PT (1) PT2289540E (pt)
RU (1) RU2436590C1 (pt)
UY (1) UY32670A (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302312A (zh) * 2011-12-19 2015-01-21 Lfb美国股份有限公司 用于炎性病症治疗的重组人α-1-抗胰蛋白酶
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP3291730B2 (ja) * 1991-05-14 2002-06-10 エルニア スノラソン 疲労症候群の治療
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU5311401A (en) * 2000-04-21 2001-11-07 Upjohn Co Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002006837A1 (en) * 2000-07-14 2002-01-24 Matsushita Electric Industrial Co., Ltd. Particle-labeled protein and immuno-chromatograph using the same
JP2006508971A (ja) 2002-11-20 2006-03-16 アライバ−プロメティック インコーポレイティド プロテアーゼ阻害剤を使用して炎症性疾患を治療する組成物及び方法
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
CA2536918A1 (en) * 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
EP1786923A1 (en) * 2004-09-07 2007-05-23 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) * 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
WO2008143633A2 (en) * 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
JP2010540527A (ja) * 2007-09-25 2010-12-24 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物
EP2214699B1 (en) 2007-11-02 2016-11-30 Grifols Therapeutics Inc. Method, composition, and article of manufacture for providing alpha-1 antitrypsin

Also Published As

Publication number Publication date
AU2010202203B2 (en) 2012-08-23
US9205134B2 (en) 2015-12-08
RU2436590C1 (ru) 2011-12-20
UY32670A (es) 2011-01-31
CA2706212A1 (en) 2010-12-30
US20100331261A1 (en) 2010-12-30
CA2706212C (en) 2014-02-04
CL2010000575A1 (es) 2011-10-28
ES2332645A1 (es) 2010-02-09
JP5231490B2 (ja) 2013-07-10
EP2289540A1 (en) 2011-03-02
CN101934071A (zh) 2011-01-05
PL2289540T3 (pl) 2013-03-29
MX2010006125A (es) 2011-01-05
JP2011012060A (ja) 2011-01-20
ES2392691T3 (es) 2012-12-12
ES2332645B1 (es) 2010-10-18
HK1148198A1 (en) 2011-09-02
NZ585890A (en) 2011-11-25
AU2010202203A1 (en) 2011-01-20
AR077123A1 (es) 2011-08-03
CN101934071B (zh) 2012-11-28
EP2289540B1 (en) 2012-08-22
BRPI1002087B1 (pt) 2019-07-02
PT2289540E (pt) 2012-12-04

Similar Documents

Publication Publication Date Title
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
BR112013003677A2 (pt) uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2011041632A3 (en) Combination therapies for the treatment of obesity
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
BR112016021985A8 (pt) formulação farmacêutica e composto
BRPI1002087A2 (pt) Uso de alfa-1-antitripsina para a preparação de medicamentos para o tratamento da síndrome da fadiga crônica
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
WO2011009115A3 (en) Combination therapies for the treatment of obesity
AR080541A1 (es) Tratamiento para la endometriosis
BRPI0918593B8 (pt) composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas
RU2013127794A (ru) Фармацевтическая комбинация и композиция для лечения ожирения и ее применение

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.